Pablo Bartolucci
Overview
Explore the profile of Pablo Bartolucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
1488
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arlet J, Herquelot E, Lamarsalle L, Raguideau F, Bartolucci P
Br J Haematol
. 2025 Feb;
PMID: 39948690
No abstract available.
2.
Razazi K, Berti E, Cecchini J, Carteaux G, Habibi A, Bartolucci P, et al.
PLoS One
. 2025 Feb;
20(2):e0319527.
PMID: 39937752
[This corrects the article DOI: 10.1371/journal.pone.0302298.].
3.
Ilboudo Y, Brosseau N, Lo K, Belhaj H, Moutereau S, Marshall K, et al.
Hum Mol Genet
. 2025 Jan;
PMID: 39886999
Sickle cell disease (SCD) is the most common monogenic disease in the world and is caused by mutations in the β-globin gene (HBB). Notably, SCD is characterized by extreme clinical...
4.
Raynor A, Jacquel B, Francois S, Fellahi S, Mouri N, Berquet C, et al.
Br J Haematol
. 2025 Jan;
206(2):749-752.
PMID: 39761661
No abstract available.
5.
Idowu M, Otieno L, Dumitriu B, Lobo C, Thein S, Andemariam B, et al.
Lancet Haematol
. 2024 Dec;
12(1):e35-e44.
PMID: 39644907
Background: Sickle cell disease, a debilitating, inherited haemolytic anaemia with premature morbidity and mortality, affects millions globally. Mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase, improves red blood cell...
6.
Bartolucci P
Hematology Am Soc Hematol Educ Program
. 2024 Dec;
2024(1):618-622.
PMID: 39644018
This educational program outlines the importance of evolving clinical care models in response to increased life expectancy and variability in individual patient experiences, particularly in the context of sickle cell...
7.
De Luna G, Habibi A, Moutereau S, Martino S, Alhamrouni J, Morel C, et al.
Eur J Haematol
. 2024 Oct;
114(2):264-266.
PMID: 39428915
Voxelotor modifies hemoglobin-oxygen affinity improving anemia and reducing hemolysis in sickle cell patients. However, the impact of Voxelotor on fetal hemoglobin (HbF) levels is unknown. We describe here variations of...
8.
dHumieres T, Sadraoui Z, Savale L, Boyer L, Guillet H, Alassaad L, et al.
Blood Adv
. 2024 Jul;
8(21):5625-5638.
PMID: 39083808
Although patients with homozygous sickle cell anemia (SCA) carry both significant left atrial (LA) remodeling and an increased risk of stroke, the prevalence of atrial arrhythmia (AA) has never been...
9.
Messimeris D, Bismuth H, Provost C, Emaer C, Mele N, Kitenge R, et al.
Blood Adv
. 2024 May;
8(15):3993-4002.
PMID: 38815229
The prognosis of sickle cell disease (SCD) in adults is determined primarily by damage to targeted organs such as the brain. Cognitive dysfunction in SCD is a common chronic neurological...
10.
dHumieres T, Bouvarel A, Boyer L, Savale L, Guillet H, Alassaad L, et al.
Sci Rep
. 2024 May;
14(1):11095.
PMID: 38750085
This pilot study focusing on Sickle Cell Anemia (SCA) patients offers a comprehensive and integrative evaluation of respiratory, cardiovascular, hemodynamic, and metabolic variables during exercise. Knowing that diastolic dysfunction is...